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via Smad3- and Smad4-depandent pathways in synergy with bHLH transcription factors 
such as TFE3. However, deepita the presence of two Smad-binding elements and an E- 
box at the 4G / 5G polymorphism in the PAl-1 promoter, this region does not appear to be 
a major contributor to TGF-J] induction of PAl-1 promoter activity. Taken together, these 
data indicate that TGF-~ is unlikely to be an allele-selective regulator of PAl-1 gene 
expression, 
10:48 a.m. 
1007MP-130 Thrombin Activatable Flbrlnolyais Inhibitor (TAFI) 
Levels in Patients With Coronary Artery Disease 
Investigated by Anglography 
Tushar Oh~atteriee, Verena Schroeder, Martin Fleisch, Stefan Windecker, Christian Seller, 
Franz R. Ebadi, Bernhard Meier, Hans P, Kohler, Swiss Cardiovascular Center Bern, 
University Hospital, Inselspital, Bem, Switzerland, Laboratory for Thrombosis Research, 
University Hospital, Inselspital, Bern, Switzerland. 
Background: Thrombin activatable fibrinolysis inhibitor (TAFI), also known as plasma 
procarboxypeptidase B or carboxypeptidase U, is a recently described component which 
is involved in the regulation of the balance between coagulation and fibrinolysis. When 
activated by the thrombin-thrombomodulin complex, TAFI leads to a potent inhibition of 
tPA-inducad fibrinolysis. High TAFI antigen plasma levels may therefore contribute to an 
increased dsk for thrombotic disorders. There are no data available about TAFI antigen 
levels in patients with coronary artery disease (CAD) and subjects free of CAD both 
investigated by angiography. 
Material and Methods: 123 subjects admitted for angiography for investigation of CAD 
were studied. 81 subjects had 1,2 or 3 vessel disease, 42 subjects were free of CAD and 
used as controls. TAFI antigen levels were analysed in citrated blood samples which 
were taken from the ostium of the left coronary artery. TAFI antigen levels were deter- 
mined with a commercially available sandwich ELISA (Kordia, Leiden, The Netherlands). 
Results: TAFI antigen presented a large range of values, with a 2- to 3-fold increase 
between the 10th and 90th percentiles in patients and controls (mean: 129,3%). CAD 
patients had higher plasma TAFI antigen levels compared to controls. (135,25 % vs 
114.2 %; p=0.01). TAFI antigen levels remained significant between the groups after 
adjustment for cholesterol, triglycedde, gender and smoking (p<0.05). 
Conclusion: These findings suggest that increased TAFI antigen levels determined in 
arterial coronary blood may represent a risk factor for CAD. Because of the large interin- 
dividual variability of TAFI antigen levels in plasma, genetic control may be involved. Fur- 
ther studies are required to evaluate the significance of the observed changes in TAFI 
antigen levels in relation to the development of CAD. 
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1008-71 Arteriogeneais on Demand in Exercising Mice 
Expressing FGF-2 Under the Control of the 
Phoaphoglycerate Klnase Promoter 
Swen Wolfram. Tibor Ziegelhoeffer, Borja Fernandez, J. Douglas Coffin, Shawn Wagner, 
Attain Helisch, Wolfgang Schaper, Max-Planck-lnstitute, Department of Experimental 
Cardiology, Bad Nauheim, Germany. 
Background: Fibroblest growth factor 2 (FGF-2), a potent mitogen for endothelial and 
vascular smooth muscle cell, is implicated in arterial and capillary growth. Exercise is 
beneficial for patients with peripheral arterial obstructive disease (PAOD) considering calf 
blood flow, maximal walking distance, and capillary growth. This study investigated the 
role of regular endurance exercise in a model of PAOD in transganic mice overexpress- 
ing FGF-2. 
Methods: The right femoral arteries of 12 transgenic mice overexprossing FGF-2 and 12 
nontransgenic littermates (FVB/n) mice were occluded. The mice were randomly 
assigned to a sedentary group and a group, which was trained 6 days/week on a mouse 
treadmill. At the end of the exercise program (5 weeks) foot blood flow was determined 
by Laser Doppler Imaging (LDI). Gastrocnemius blood flow was measured using Mag- 
netic Resonance Imaging (MRI). Exercise capacity of all groups was determined by a 
graded exercise test. Postmortem angiograms and histomorphometry of collateral arter- 
ies were performed. 
Results: Only trained FGF-2 transgenic mice demonstrated significantly improved blood 
flow determined by both LDI and MRI when compared to sedentary nontransgenic mice. 
LDI of foot (right/left ratio): 0.97 ± 0.03 vs. 0.66 ± 0.10 
MRI of gastrocnemius (ml/min/g) occluded leg: 0.85 ± 0.06 vs. 0.60 ± 0.06 
MRI of gastrocnemius (ml/min/g) normal leg: 1.16 ± 0.11 vs. 0.83 ± 0.06 
Exercise capacity of trained FGF-2 transgenic animals was dramatically improved (308% 
of sedentary nontransgenic mice). Postmortem angiograms showed the formation of a 
dense collateral network in trained FGF-2 transgenic mice. Histomorphometry of collater- 
als confirmed the angiographic findings of a changed collateral growth pattern in trans- 
genic mice due to exercise. 
Conclusion: Trained FGF-2 transgenic mice demonstrate increased blood flow to the foot 
and to the gastrocnemius, improved exercise capacity, and the formation of a dense col- 
lateral artery network. This study indicates that only sufficient FGF-2 application and 
endurance training lead to improved collateral artery growth. This might be a relevant 
therapeutical approach for humans suffering from PAOD. 
1008-72 Endothelial Progenitor Cell Release in Patients With 
Coronary Artery Disease After Maximal Symptom- 
Limited Exercise Test 
Karsten Lenk. Volker Adams, Dominik Lenz, Atile Tarnok, Sandra Erbs, Gerhard Schuler, 
Rainer Hambrecht, University of Leipzig, Heart Center, Leipzig, Germany. 
Background: Increasing evidence suggests, that endothelial progenitor cells (EPC) play 
an important role in postnatal naovascularization, As animal studies propose ischemia 
seems to be one of the main triggers for the release of EPCs from the bone marrow. Until 
now, however, less is known about the impact of an acute myocardial ischemia on the 
EPC release. Therefore, the aim of this study was to investigate the release of EPCs in 
response to a maximal symptom-limited exercise in patients with symptomatic oronary 
artery disease (CAD). 
Methods: In six patients and six healthy controls blood was taken before and 8, 24 and 
48 hours after a maximal symptom-limited exercise test. Exercise tests were stopped in 
patients due to progressive angina pectoris and/or significant ST segment depression at 
95,8± 10Watt. Mononuclear cells (MNC) were isolated and cultured. After 4 days adher- 
ent EPC were characterized by Di-acLDL uptake and concomitant FITC-lectin binding. 
Double positive cells were counted by Laser Scanning Cytomater (LSC). The endothelial 
origin was further documeted by demonstrating the expression of KDR, vWF and VE- 
cadherin. 
Results: 
~ CAD 
"~ c 
Oh 8h 24h 48h 
*p~0.05 vs Oh #p<0.05 vs control 
Conclusions: These results demonstrate for the first time that in patients with CAD even 
a very short episode of myocardial ischemia is sufficient o induce a considerable release 
of EPCs. 
1008-73 Ch imer ic  Vascu la r  Endothelial Growth Factor Fusion 
Protein Selectively Inhibits FIk-1 Endothelial Progenitor 
Cells 
Jonathan M, Hill, Marina V. Backer, Joseph M. Backer, Toren Finkel, National Institutes of 
Health, Bethesda, Maryland. 
Endothelial progenitor cells (EPCs) contribute to postnatal vasculogenesis in tumors and 
potentially regulate atherosclerotic plaque size. Selective destruction of EPCs may there- 
fore have therapeutic benefit in certain clinical settings. We have made use of the fact 
that EPCs express high levels of the receptor for vascular endothelial growth factor-2 
(VEGFR-2/FIk-1), An active fusion protein SLT-VEGF/L, containing the catalytic A-sub- 
unit of Shiga-like toxin fused to VEGF121 end a control fusion protein SLT-VEGF/Lci con- 
taining a catalytically inactive mutant of SLT A-subunit (Yl14S and R170L amino acid 
substitutions) fused to VEGF121 were constructed, expressed and purified, EPCs were 
isolated from human peripheral blood mononuclear cells using density gradient centrifu- 
gallon and seeded on fibronectin-ccated plates. An endothelial phenotype of the 
fibronectin-adherant ceils was confirmed by immunohistochemical analysis for Tie-2, 
CD31 and VEGFR-2, and by ability of these cells to uptake Dil-labeled acetylated LDL. A 
dose response curve demonstrated that EPC colony formation was inhibited by SLT- 
VEGF/L with an IC50 of 0.5 nM. This inhibitory effect is -1000-fold more efficacious than 
angiostatin, another reported inhibitor of EPC activity. In contrast, the catalytically inac- 
tive fusion protein SLT-VEGF/Lci did not affect EPC colony formation. Human umbilical 
vein cells (HUVECs) expressing, 2-5 xl04 VEGFR-2/celI, and porcine aortic endothelial 
cells (PAE/KDR) engineered to expressed 2-3x105 VEGFR-2/cell were employed for 
evaluating the effects of SLT-VEGF/L on endothelial cells with different VEGFR-2 density. 
HUVECs were relatively insensitive to SLT-VEGF/L at concentrations up to 20 nM while 
PAE/KDR cells had an IC50 below 1 riM. In summary, a chimeric toxin can inhibit EPC 
activity, cluster and spindle cell formation. This inhibition is a function of high VEGFR-2/ 
FIk-1 expression on these cells. Native endothelisr cells are at least 40-fotd less sensitive 
to the effects of the chimeric toxin. These results suggest the potential clinical applicabil- 
ity of this chimeric toxin for the selective ablation of EPC activity. 
1008-74 Tissue Factor Inhibition Impairs the Maturation of  
Neovascularization in Postnatal Angiogenesis 
Frederic Mououet, Katy Didier, Dalphine Corseaux, AIbin Pourtier, Sylvie Vincent, 
Chantal Vercamer, Bernard Vandenbunder, Chdstophe Bauters, Brigitte Jude, Eric Van 
Belle, Hopital Cardiologique, Lille, France, Institut de Biologie de Lille, France. 
Tissue factor (TF) has an important role in vasculogenesis and tumoral angiogenesis. 
However, its role in post-natal non-tumoral angiogenesis is unknown. We investigated TF 
inhibition effects in a murine model of angiogenesis. Micro-implant loaded with basic 
Fibroblast Growth Factor (bFGF) were grafted in ears of balb/c mice, inducing a local 
angiogenesis. TF was inhibited after systemic injection of an active site-inhibited FVll 
(ASIS, gift from Novo Nordisk). Angiogenic response was accurately quantified by histo- 
logical techniques. Five mice were grafted with control implants. Seventeen were grafted 
with implants loaded with 100 ng bFGF; eight received systemic injection of ASIS (5 ~g/ 
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g) once a day for 5 days, nine received placebo. At day 14, animals were sacrificed and 
angiogenesis analysed by counting vessels on histological sections. 
RESULTS (shown in the table below): CD 31 quantification pointed out a minimal anglo- 
genesis induced in control implants, significantly increased in bFGF implants, and sur- 
prisingly enhanced in bFGF+ASIS implants. However, TF inhibition significantly 
decreased the number of perfusad vessels, as shown by CD31 peffusad vessels quanti- 
fication and May Grunwald Giemsa quantification. 
CONCLUSION: TF inhibition does not inhibit bFGF-induced angiogenesis, but rather 
impairs neovasculadzation maturation, with a dramatical decrease of perfused bFGF- 
induced vessels. These results indicate the critical role of TF in post-natal non-tumorel 
angiogenesis. 
CD31 total CD31 perfused May Grunwald 
vessels vessels Giemsa 
control (n=5) 70+/20 64+/-13 42+/-27 
bFG F + placebo (n=9) 140+/-34 * 104+/-35 104+/-26 
bFGF+ ASIS (n=8) 182+/-66 * 59+/-9 "i" 56+/-16 1 
• P<0.0001 vs placebo. 1"P<0.0001 vs bFGF 
1008-75 A Growth Factor Mixture That Significantly Enhances 
Collateral Growth 
Wilfded Roethv, Eduard Fiehn, Kotaro Suehiro, Anguo Gu, Geng Hua Yi, Juichire 
Shimizu, Jie Wang, Geping Zhang, John Ranieri, Rama Akella, James Benedict, Daniel 
Burkhoff, Columbia Universi~ New York, New York, Sulzer Inc., Austin, Texas. 
Background: Studies of therapeutic angiogenesis have focused on use of single growth 
factors. However, angiogenesis is complex and multiple factors participate on the cas- 
cade. Moreover, recent publications have identified synergistic effects of angiogenic 
agents in the induction of vascular growth. We tested the efficacy of a naturally occurring 
growth factor mixture (GFm) isolated from bovine bones and previously shown to stimu- 
late angiogenesis more potently than single growth factors. 
Methods: Components of GFm (SDS-PAGE, mass spectrometry and Western blot) 
include transforming growth factor beta 1-3, bone morphogenic protein 2-7, and fibre- 
blast growth factor 1. To evaluate the angiogenic potential, a randomized, blinded, pla- 
cebo-controlled study was performed. An LAD amereid constrictor was placed in 21 dogs 
to create chronic ischemia. 3 weeks later, angiography confirmed ameroid closure and 
defined the degree of collateral filling of the distal LAD. Dogs were randomized into 3 
groups: GFml (1 mg/ml), GFmt0 (10 mg/ml) or placebo (P), each injected into ischemic 
myocardium (15-20 injections/heart, 0.15 ml/injection) via thoracotomy. Animals received 
bromodeoxyuddioe (BrdU) injections to label proliferating cells. 6 weeks later angiogra- 
phy studies were repeated. Hearts were removed and evaluated histologically. Histology 
and angiograms were graded with semiquantitative scales. Aft analyses were done 
blinded to treatment group. 
Results: Histologically, GFm dose dependently induced growth of large, BrdU positive 
vessels (vascular growth index: 0.2±0.2, 1.0±0.2, 1.7±0.2 in P, GFml and GFml0, 
respectively; p=0.001). Angiogrephically, opacification of the distal LAD significantly 
improved with GFm (distal LAD opacification score: 0,4±0.2, 1.1±0.14, 1.6±0.3 in P, 
GFm I and GFml0, respectively; p=0,014). 
Conclusion: GFm is a potent angiogenic agent that stimulates large vessel growth in 
chronically ischemic myocardium in a dose dependent manner, Collateral vessels devel- 
oped to the occluded LAD to significantly improve or completely reconstitute its visualiza- 
tion during contrast injection. 
1008-76 Trans-Epicardial Transplantation of Mature Endothelial 
Cells Induces Neoangiogenesis and Improves LV 
Function in an Animal Model of Ischemic 
Cardiomyopathy 
v. Chekanov, V. Nikolaychik, G. Tchekanov, G. Dangas, G. Roubin, M. B. Leon, J, W. 
Moses, Nicholas N. Kioshidze. Lenox Hill Heart and Vascular Institute, New York, New 
York, Heart Care Associates and Milwaukee Heart Institute, Milwaukee, Wisconsin. 
Objective: We hypothesize that transplantation of heterotepic mature endothelial cells 
(EC) within a fibrin platform would increase production of endogenous growth factors and 
promote development of a functional capillary network. The objective of this study was to 
investigate the effect of autologous EC transplantation using a fibrin meshwork on 
ischemic myocardium of sheep. 
Methods: Placing ameroid constrictors on the circumflex artery of 12 adult sheep pro- 
duced ischemic cardiomyopathy. Three groups were randomized (4 animals/greup) to 
transepicardial injection (3 sites/animal), 4 weeks after amereid placement: sham treat- 
ment (saline with denatured cells), controls (no injections), and EC fibrin meshwork 
(autologous mature EC, 5x105 per injection site, harvested from jugular veins). Eight 
weeks after trans-epicardial treatment animals were assessed for myocardial function 
(echo), myocardial flow, histology (capillary area) and myocardial ultrastructure (TEM). 
Results: Eight weeks after EC/sham/control treatment, EF was markedly improved in the 
EC transplant group (0.56+-0.04 p=0.029 versus baseline), whereas in the sham and 
control groups, EF deteriorated (0.40+-0.08 p= 0.013 Vs EC and 0.39+-0.05 p=0.0017 
Vs EC group respectively). Myocardial blood flow (ml/min/g) measured with colored 
microspheres was also significantly increased in the EC transplant group (0.66+-0.10 
versus 0.15+-0.03 in control and 0.18+-0.05 in saline group; p=0.0009 Vs control and 
p=0.0001 Vs saline). In the EC transplant zones, histology revealed extensive neovascu- 
larization (significant increase in capiflary area) and TEM demonstrated functional arteri- 
oles and cappilaries. 
Conclusion: Trans-epicardial heterotopic transplantation of EC within a fibrin matrix dra- 
matically enhances neovascularization, increases myocardial blood flow and improves 
LV function in an animal model of ischemic cardiomyopathy. The fibrin meshwork plat- 
form may serve as a generalized enhancement vehicle for other stem cell transplant 
methodologies to treat pts with refractory ischemia and/or LV dysfunction. 
1008-77 Long-Term Safety and Efficacy of Intramuscular 
Administration of  C1-1023 (AdGVVEGF121.10) in 
Patients With Intermittent Claudication 
San!av Ra!aeooalan, Jeffrey D. Trechtenberg, Jeffrey W. Olin, Emile R. Mohler, III, 
Raphael Pak, Angelo Secci, Scott McBride, Henrik Rasmussen, Ronald G. Crystal, 
University of Michigan, Ann Arbor, Michigan. 
Background. In a Phase I study, we evaluated the safety and efficacy of C1-1023 
(AdGvVEGF121.10, adenovirus encoding vascular endothelial growth factor121) in 
patients with advanced intermittent claudication (IC) secondary to SFNinfrageniculate 
disease. 
Methods: Patients were randomized to IM dosing of placebo (n=3) or C1-1023 (4 x 108 to 
4 x 101° particle units, n= 15). 
Results: 73% and 33% of C1-1023 and placebo patients respectively completed 1 year of 
follow-up. Edema and rash were the most common early adverse event with 47% of CI- 
1023 subjects developing edema (mild- moderate) in the injected extremity. One infra- 
inguinal bypass procedure occurred in the placebo and C1-1023 groups at day 29 and 
104 respectively. One death (day 160) and one malignancy (day 274) occurred in the CI- 
1023 group, none were judged related to C1-1023. Table 1 summarizes the median 
change in peak walking time (PW-F), claudication onset time (COT) and ankle brachial 
indices (ABI) for the C1-1023 group. 
30 days 90 days 180 days 360 days 
Rest ABI 0.04, 0.11 (14) 0.21", 0.13(6) 0.09*, 0.30 (12) 0.09", 0.06 (9) 
Stress ABI -0.06, 0.13 (7) 0.02, 0.06 (4) -0.09, 0.13 (6) -0.08, 0.10 (4) 
~COT 0.5,0.8(4) 0.2, 1.8(2) 0.1, 1.1 (3) 0.5, 0 (1) 
A PWT 1.0", 0.7 (8) 2.0, 5.0 (4) 2.0, 4.1 (7) 4.8, 5.5 (4) 
All values are Median, Inter-quartile range (75 th - 25 th percentile). Parenthesis = Number 
of patients with data at baseline and time point. * p < 0.05 by signed rank test 
The walking distance perception score in the walking impairment questionnaire showed 
an improvement at 30 days corresponding to the improvement in PWT. 
Conclusions: Administration of C1-1023 to IC patients was adequately tolerated and 
associated with an apparent improvement in clinical outcomes upto 1 year. Larger stud- 
ies with placebo controls in IC are ongoing. 
1008-78 Induct ion  o f  Angiogenesis by Metalloproteinase 
Der ived From Venom of Indian Cobra in a Mode l  o f  Rat 
Hind  L imb Ischemia 
Sundeee Mishra. Sujata Sharma, Gauthaman Karunakaran, Subir K. Maulik, Ruma Ray, 
Shyarn S. Chauhan, Suruchi Chopra, Sanjiv Sharma, Rajiv Narang, Prem Chopra, Tej P, 
Singh, Subhash C. Manchaoda, All India Institute of Medical Sciences, New Delhi, India. 
Background: The field of therapeutic aogiogenesis has evolved from formation of capil- 
lary sprouts to development of arterial collaterals (arteriogenesis), One of the shortcom- 
ings of strategies designed solely to stimulate proliferation of endothelial cells (ECs) such 
as VEGF therapy, is the fact that only capillary (<40pro) networks are formed. Instead, 
formation of large conductance arterioles require a series of sequential steps involving 
EC migration, adhesion and differentiation and smooth muscle cell (SMC) migration. 
Venom from indian cobra contains several potent enzymes including metalloproteinases 
(MP). We undertook the present study to test efficacy of MP and phospholipase A2 (PLA- 
2) derived from venom of Indian cobra and compare it with plasmid VEGF 165 (ph VEGF 
165) gene. 
Methods : Male Wister albino rats (6 in each group) were randomized to receive MP lmg/ 
kg, PLA-2 2.Smg/kg, ph VEGF 165 400pg or normal saline (control), 2 days after left fem- 
oral artery division. Fifteen days after femoral artery division, digital subtraction angiogra- 
phy (DSA) was performed and muscles of thigh distal to the site of division subjected to 
histopathological examination. 
Results : On DSA there was a mild increase in number of large arterial collaterals both in 
MP and pH VEGF 165 groups as compared to PLA.2 or saline groups (statistically not 
significant). Histopathological examination revealed that there was a marked stimulation 
of neo-angiogenesis in the MP group and ph VEGF group as compared to PLA-2 or the 
saline group. Capillary density score was : saline, 1.1 ± 1.0; PLA-2, 1.2 ± 1.0; MP, 2.0 ± 
0.9 (p<0.05 vs saline group) ph VEGF, 2.3 ± 1.1 (p<0,05 vs saline group). There was a 
marked inflammatory response in the injected muscles in the MP group. 
Conclusions : Metalloproteinase derived from venom of Indian cobra can lead to pro- 
found angiogenesis comparable to that produced by VEGF gene therapy. Further studies 
are warranted to confirm its efficacy and to evaluate the role of co-edministration with 
other angiogenic agents. 
